Figure 1.
Unbound and total rivaroxaban plasma concentrations on day 6 after the last dose of rivaroxaban with different andexanet alfa dosing regimens. (A) Unbound rivaroxaban (cohorts 1-3, upper left panel; cohorts 4-5, upper right panel). (B) Total rivaroxaban (cohorts 1-3, lower left panel; cohorts 4-5, lower right panel). Andexanet alfa was dosed at 3 hours after the last dose of rivaroxaban with a 210-, 420-, and 600-mg bolus (cohorts 1-3), 720-mg bolus plus 4 mg/min × 1-hour infusion (cohort 4), and 800-mg bolus plus 8 mg/min × 2-hour infusion (cohort 5), respectively.

Unbound and total rivaroxaban plasma concentrations on day 6 after the last dose of rivaroxaban with different andexanet alfa dosing regimens. (A) Unbound rivaroxaban (cohorts 1-3, upper left panel; cohorts 4-5, upper right panel). (B) Total rivaroxaban (cohorts 1-3, lower left panel; cohorts 4-5, lower right panel). Andexanet alfa was dosed at 3 hours after the last dose of rivaroxaban with a 210-, 420-, and 600-mg bolus (cohorts 1-3), 720-mg bolus plus 4 mg/min × 1-hour infusion (cohort 4), and 800-mg bolus plus 8 mg/min × 2-hour infusion (cohort 5), respectively.

Close Modal

or Create an Account

Close Modal
Close Modal